Boehringer Ingelheim and ViraTherapeutics Collaborate on Oncolytic Virus Therapies

ViraTherapeutics will develop its VSV-GP therapy alone and in combination with other therapies.
Oct 03, 2016
By Pharmaceutical Technology Editors

Boehringer Ingelheim and ViraTherapeutics today announced a long-term collaboration to jointly develop a next-generation oncolytic virus therapy platform and to investigate ViraTherapeutic’s lead candidate Vesicular Stomatitis Virus glycoprotein (VSV-GP) alone and in combination with other therapies. ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic virus therapies, has developed its novel technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund (BIVF) and will now be responsible for preclinical and clinical testing of VSV-GP in Phase I trials. Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development.

“We are very excited about this new collaboration with ViraTherapeutics, a company for which the Boehringer Ingelheim Venture Fund is a core investor,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors responsible for Innovation, in a press release. “Oncolytic viruses are among the most promising new therapy approaches in cancer research, and the technology developed by ViraTherapeutics may offer significant advantages compared to others currently under development. The new collaboration is an example of Boehringer Ingelheim’s increasing focus on partnering and further complements the company’s growing immune-oncology pipeline that includes among others, a therapeutic cancer vaccine and next-generation checkpoint inhibitors.”

Oncolytic virus therapy is a cancer treatment approach that uses a virus that infects and breaks down cancer cells. Tumor antigens that are normally hidden from the immune system inside the cells are released, triggering an immune response to fight the tumor. VSV-GP has a shorter replication time than other oncolytic virus platforms currently under development. This oncolytic virus does not integrate in the DNA and has been modified to avoid neural inflammation associated with wild-type viruses. In VSV-GP, the glycoprotein of the Vesicular Stomatitis Virus has been replaced by the glycoprotein of the Lymphocytic Choriomeningitis Virus (LCMV) to conceal the virus from the immune system. In preclinical models, it did not induce virus-neutralizing antibodies, potentially enabling repeated administration.

Source: Boehringer Ingelheim

 

native1_300x100
lorem ipsum